Unknown

Dataset Information

0

Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/?CD40 therapy.


ABSTRACT: Fas ligand expression in certain tumors has been proposed to contribute to immunosuppression and poor prognosis. However, immunotherapeutic approaches may elicit the Fas-mediated elimination of immunosuppressive regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) within tumors that represent major obstacles for cancer immunotherapy. Previously, we showed that IL-2 and agonistic CD40 Ab (?CD40) elicited synergistic antitumor responses coincident with the efficient removal of Tregs and MDSCs. We demonstrate in this study in two murine tumor models that Treg and MDSC loss within the tumor microenvironment after IL-2/?CD40 occurs through a Fas-dependent cell death pathway. Among tumor-infiltrating leukocytes, CD8(+) T cells, neutrophils, and immature myeloid cells expressed Fas ligand after treatment. Fas was expressed by tumor-associated Tregs and immature myeloid cells, including MDSCs. Tregs and MDSCs in the tumor microenvironment expressed active caspases after IL-2/?CD40 therapy and, in contrast with effector T cells, Tregs significantly downregulated Bcl-2 expression. In contrast, Tregs and MDSCs proliferated and expanded in the spleen after treatment. Adoptive transfer of Fas-deficient Tregs or MDSCs into wild-type, Treg-, or MDSC-depleted hosts resulted in the persistence of Tregs or MDSCs and the loss of antitumor efficacy in response to IL-2/?CD40. These results demonstrate the importance of Fas-mediated Treg/MDSC removal for successful antitumor immunotherapy. Our results suggest that immunotherapeutic strategies that include exploiting Treg and MDSC susceptibility to Fas-mediated apoptosis hold promise for treatment of cancer.

SUBMITTER: Weiss JM 

PROVIDER: S-EPMC4048774 | BioStudies | 2014-01-01

REPOSITORIES: biostudies

Similar Datasets

2010-01-01 | S-EPMC2805053 | BioStudies
2008-01-01 | S-EPMC2887390 | BioStudies
1000-01-01 | S-EPMC4480750 | BioStudies
2018-01-01 | S-EPMC6721845 | BioStudies
2015-01-01 | S-EPMC4322895 | BioStudies
1000-01-01 | S-EPMC3696683 | BioStudies
1000-01-01 | S-EPMC5728145 | BioStudies
2012-01-01 | S-EPMC3476240 | BioStudies
2012-01-01 | S-EPMC3261323 | BioStudies
2009-01-01 | S-EPMC2757307 | BioStudies